Zacks Investment Research | Nov 01, 2016 10:03PM ET
Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) reported adjusted earnings of 54 cents per American Depositary Share (ADS) in the third quarter of 2016, beating the Zacks Consensus Estimate of 52 cents. Also, earnings per ADS increased from 43 cents earned in the year-ago quarter.
Revenues increased 9% at constant currency on a year-over-year basis to $4,598 million and beat the Zacks Consensus Estimate of $4,561 million.
Segment Details
Net Healthcare revenues grew 10% to $3.73 billion, with significant contribution from the North American market. Dialysis product revenues increased 4% to $864 million.
By geography, North America revenues rose 10% year over year to $3,300 million. Health care services revenue grew 10% to $3,068 million. Revenues from the care Coordination business grew an impressive 29% to $618 million. Dialysis business grew by 6% in the reported quarter.
EMEA revenues increased 2% year over year to $675 million. Health care services revenues increased 8% (up 10% at constant currency) to $335 million driven by higher contributions from acquisitions (8%). Dialysis treatments increased 9% in the reported quarter. Dialysis products’ revenue decreased 3% (down 1% at constant currency) to $340 million primarily attributed to lower sales of dialyzers, machines, renal pharmaceuticals and bloodlines.
Revenues from Asia-Pacific grew 8% to $427 million. Net Health Care revenues were $192 million driven by 5% growth in dialysis treatments. The product business surged more than 11% at constant currency to $235 million, owing to strong sales performance across the entire dialysis products range.
Latin America revenues increased 9% to $192 million. Health care services revenue increased 6% to $139 million (up 31% at constant currency) on the back of higher organic revenue per treatment primarily driven by a retrospective reimbursement rate increase, contributions from acquisitions and growth in same market treatments. Dialysis treatments increased 19% to $53 million. This was due to higher sales of dialyzers, concentrates and bloodlines.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.